Michael Levin

And so then what that means is that nasty mutations like KRAS and things like that, these really tough oncogenic mutations that cause tumors, if you do them but then artificially

control of the bioelectrics, you greatly reduce tumorigenesis or normalize cells that had already begun to convert.

Basically, they go back to being normal cells.

And so this is another, much like with the planaria, this is another way in which the bioelectric state kind of dominates what the genetic state is.

So if you sequence the nucleic acids, you'll see the KRAS mutation.

You'll say, well, that's going to be a tumor.

But there isn't a tumor because bioelectrically you've kept the cells connected and they're just working on making nice skin and kidneys and whatever else.

So we've started moving that to human glioblastoma cells and we're hoping for a patient in the future interaction with patients.

I think so.

Yeah, I think so.

I think the actual cure, I mean, there are other technology, you know, immune therapy, I think it's a great technology.

Chemotherapy, I don't think is a good technology.

I think we got to get off of that.

Yeah, well, chemotherapy hopes to kill more of the tumor cells than of your cells.

That's it.

It's a fine balance.

The problem is the cells are very similar because they are your cells.

And so if you don't have a very tight way of distinguishing between them, then the toll that chemo takes on the rest of the body is just unbelievable.

Exactly.

Yeah, I think that's potentially a very good approach.